A neurotransmitter previously thought to only calm neurons may also play a role in waking them up, according to a study published in the journal PLOS Biology, a discovery which upends conventional theories of how the neurotransmitter works in the brain.
Investigators at Northwestern Medicine and the Flatiron Institute have characterized how developing cells reorganize their cytoplasm as part of their growth, according to a study published in Nature Physics, a discovery which furthers the field’s understanding of basic cellular processes at the earliest stages of development.
Even mild and moderate side effects can contribute to patients with cancer discontinuing their treatment, according to an analysis recently published in the Journal of Clinical Oncology.
Increased expression of specific genes in prostate cancer patients may predict whether or not the cancer will respond well to hormone therapy, according to a new study published in Nature Communications.
An individual retinal cell can output more than one unique signal, according to a Northwestern Medicine study published in Nature Communications, a finding which sheds new light on the complexities of how vision functions in mammals.
Lauren Wakschlag, PhD, professor of Medical Social Sciences, Pediatrics and Psychiatry and Behavioral Sciences, has been awarded the Paula H. Stern Award for Outstanding Women in Science and Medicine by the Northwestern Medical Women Faculty Organization.
Anti-inflammatory drugs alone are not sufficient to prevent pancreas inflammation following a common endoscopic procedure, according to a study recently published in The Lancet.
The Pfizer BioNTech BNT162b2 vaccine was highly effective in preventing severe COVID-19 infections in children and adolescents during the Delta and Omicron variants, according to a large, national study recently published in the Annals of Internal Medicine.
A lack of cancer progression could be used as a surrogate for overall survival in newly metastatic prostate cancer clinical trials, according to a new meta-analysis published in the Journal of Clinical Oncology.
An experimental drug designed to block blood-clotting proteins may slightly lower the risk of recurrent strokes, according to a dose-finding trial published in The Lancet Neurology.